Switzerland· 67529007
ZOLGENSMA, Solution for Infusion,
A onasemnogene abeparvovec product, registered in Switzerland by Novartis Pharma Schweiz AG and dispensed under Swissmedic category A. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Onasemnogene abeparvovec is registered in 14 of 19 countries.
Countries holding a registration under ATC M09AX09 (onasemnogene abeparvovec), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Onasemnogene abeparvovec · ATC M09AX09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Manufacturer
- Novartis Pharma Schweiz AG
- Country
- Switzerland (CH)
- ATC code
- M09AX09
- ATC class
- Onasemnogene abeparvovec
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
19 interactions on record for onasemnogene abeparvovec.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Onasemnogene abeparvovec · interactions on record
19 records
- 4 severe
- 15 moderate
Most severe, free to view
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- LeflunomideL04AK01severe
- TeriflunomideL04AK02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M09AX09
Onasemnogene abeparvovec, as other registers publish it.
- FinlandItvismaNovartis Europharm Limited
- PolandItvismaNovartis Europharm Limited
- United StatesITVISMANovartis Gene Therapies, Inc.
- CzechiaITVISMANovartis Europharm Limited, Dublin
- United StatesITVISMANovartis Innovative Technologies Inc.
- United StatesITVISMANovartis Innovative Technologies Inc.
- NetherlandsItvisma 1,2 × 1014 vectorgenomen oplossing voor injectieNovartis Europharm Limited
- BelgiumItvisma 1.2 10*14 vgNovartis Europharm
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1c05de7-a565-4697-a319-a91b6843a129 GET /v1/drugs/f1c05de7-a565-4697-a319-a91b6843a129?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about onasemnogene abeparvovec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.